# Impact of Lazertinib Dose Modification on Effectiveness and Safety

> **NCT05716672** · — · UNKNOWN · sponsor: **Pusan National University Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT05716672
- **Lead sponsor:** Pusan National University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716672, "Impact of Lazertinib Dose Modification on Effectiveness and Safety". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05716672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*